Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.
Actively Recruiting
Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.
Actively Recruiting
Researchers are evaluating risvutatug rezetecan Ris-Rez in men with metastatic castration-resistant prostate cancer mCRPC to see how well it works compared to the best supportive or standard care, which may include hormone therapy with androgen receptor pathway inhibitors ARPI. The study aims to determine if Ris-Rez can shrink or eliminate tumors, improve survival, and enhance quality of life. It also assesses the safety and tolerability of Ris-Rez and seeks to better understand its side effects. Participants are randomly assigned to receive either Ris-Rez or physicians choice of best supportivestandard care, which may include ARPI drugs such as Enzalutamide or Abiraterone combined with Prednisone or Prednisolone. The study is conducted in a parallel design and monitors participants over a period of up to approximately 169 weeks to evaluate treatment effects. During the study, participants undergo regular assessments including radiographic scans to measure disease progression and survival, evaluations of pain progression, tumor response, prostate-specific antigen levels, and skeletal events. Safety is closely monitored by tracking adverse events and immune responses to Ris-Rez. Participants experiences with the study treatment are also collected. The total participation may last over three years, with ongoing evaluations throughout this time.
Actively Recruiting
Researchers are evaluating belimumab as an additional treatment for adults with interstitial lung disease ILD linked to connective tissue diseases CTDs such as rheumatoid arthritis, systemic lupus erythematosus, and others. ILD leads to lung inflammation and stiffness, causing symptoms like shortness of breath and cough, which significantly reduce quality of life and are the main cause of death in these patients. This study aims to see if belimumab combined with standard therapy can stabilize or improve lung function and ILD symptoms while maintaining an acceptable safety profile. Participants are randomly assigned to receive either belimumab or a placebo, both alongside standard therapy. Belimumab is given by subcutaneous injection. The study lasts for 52 weeks with treatment and monitoring occurring throughout this period. The primary measurement is the change in lung function, specifically forced vital capacity FVC, from baseline to week 52. Various secondary measures assess lung symptoms, fatigue, quality of life, lung imaging, and safety outcomes. During the study, participants will have assessments at baseline and week 52 including lung function tests, symptom questionnaires, and imaging scans. Researchers will track changes in lung capacity, disease progression, symptom severity, fatigue, and medication use. Safety monitoring continues up to week 60 to record adverse events and hospitalizations related to respiratory issues. Participants will be involved in regular visits for evaluation and medication administration over the course of the year-long study.
Actively Recruiting
Researchers are evaluating the safety and effects of daily vosoritide treatment compared to placebo in infants and young children with hypochondroplasia HCH, aged from birth up to less than 36 months. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study aims to better understand vosoritides impact on growth and health over one year in this specific young population with genetically confirmed HCH. Participants will be randomly assigned to receive either vosoritide or a placebo through daily subcutaneous injections for 52 weeks. The vosoritide dose will be adjusted based on weight bands approved for a related condition. After treatment, there will be a 2-week safety follow-up to monitor any adverse effects or changes. During the study, participants will have regular evaluations including clinical lab tests, heart rate, respiratory rate, blood pressure, and body temperature measures at several time points. Researchers will assess growth changes such as height, body segment ratios, and bone density using scans, along with monitoring adverse events and vosoritide blood levels. The total participation duration is about 54 weeks including treatment and safety follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.
Actively Recruiting
Researchers are studying Mocertatug rezetecan Mo-Rez to see how it works in treating ovarian cancer that does not respond well to platinum-based therapies. This Phase 3 trial compares Mo-Rez to standard chemotherapy treatments while evaluating its safety, tolerability, and side effects. The study is sponsored by GlaxoSmithKline and focuses on platinum-resistant ovarian cancer, including specific tumor types confirmed by tissue testing. Participants will be randomly assigned to receive either Mo-Rez or one of several standard chemotherapy options chosen by their doctor, including Paclitaxel, Pembrolizumab with or without Bevacizumab, Pegylated liposomal doxorubicin PLD, Topotecan, or Gemcitabine. The treatments will be given according to standard administration methods, and participants may continue in the study for up to approximately 212 weeks to evaluate long-term outcomes. Throughout the study, participants will undergo regular assessments including tumor scans to measure disease progression and response, blood tests, and quality-of-life questionnaires. Researchers will monitor survival rates, side effects, vital signs, laboratory values, and immune responses to the drug. Safety monitoring and patient-reported outcomes will continue for the full duration of participation, which may last over four years.
Actively Recruiting
This clinical trial is studying patients with advanced non-small cell lung cancer NSCLC who have specific alterations in the MET gene, including mutations and amplifications. The study focuses on evaluating the effects and safety of Glumetinib, a selective MET inhibitor, in adults with locally advanced or metastatic NSCLC, including pulmonary sarcomatoid carcinoma. This includes patients who have had prior treatments or are not eligible for chemotherapy. The trial is conducted in phases Ib and II with participants from China, the US, and globally. Participants receive Glumetinib orally at a dose of 300 mg once daily while fasting. The Phase Ib portion includes about 90 patients with various MET alterations, while Phase II involves around 78 patients who have METex14 skipping mutations and meet additional criteria related to prior treatments and chemotherapy eligibility. The study allows for a safety run-in group of at least six patients in the US. Treatment continues according to the study protocol to assess response and safety. Throughout the study, participants will undergo regular assessments to monitor tumor response using RECIST 1.1 criteria and to evaluate safety and side effects. Researchers will track objective response rate ORR over about one year, along with duration of response and overall efficacy. Patients must have adequate organ function and performance status to participate. The study includes follow-up visits to observe treatment effects and document any adverse events during and after the treatment period, with a total participation duration aligned with the study completion timeline.
Actively Recruiting
Researchers are evaluating the safety and clinical effects of Awiqli in people with diabetes mellitus in Japan during routine medical care. This observational study aims to collect real-world data on the use of Awiqli over a one-year period. The study focuses on participants with any type of diabetes who are prescribed Awiqli independently of the study. Participants will receive commercially available Awiqli as directed by their treating doctors according to standard clinical practice. There is no experimental treatment assignment as this is a non-interventional study. The study observes the use of Awiqli over 52 weeks without altering usual care. During the study, participants will be monitored for adverse reactions and events, serious adverse events, and changes in diabetes-related clinical parameters including HbA1c, fasting plasma glucose, and diabetes therapy-related quality of life. Data will be collected from baseline through week 52. The total participation time lasts about one year.
Actively Recruiting
Researchers are conducting a survey to monitor the safety and effectiveness of Ondexxya Intravenous Injection 200 mg in patients who have received this treatment. The focus is on understanding the occurrence of specific safety concerns, including thrombotic events, infusion reactions, and re-bleeding, in patients treated for life-threatening bleeding related to Factor Xa inhibitors. The survey gathers information under real-world use conditions to detect any unknown adverse drug reactions, assess the incidence of known adverse effects, and identify factors that may influence the safety or effectiveness of the drug. There are no assigned intervention groups, as this is an observational study collecting data from patients treated with Ondexxya. Participants are monitored for 30 days to evaluate the incidence of adverse drug reactions and safety events related to their treatment. Safety and effectiveness information is collected through routine clinical care without additional interventions. The study will continue until October 31, 2026, with outcomes focused on adverse reactions and safety specifications during the observation period.